Mark D. Pegram, MD

Articles

Experience with Trastuzumab Deruxtecan in Breast Cancer

October 21st 2021

Breast cancer experts, Sara Tolaney, MD, and Mark Pegram, MD, discuss current standard of care in sequencing of therapies in mBC and the effect of DESTINY-Breast03 data on sequencing going forward.

DESTINY-Breast03 Trial in HER2+ mBC

October 21st 2021

Mark Pegram, MD, and Sara Tolaney, MD, review the DESTINY-Breast03 study design, clinical efficacy, and safety data.

Trastuzumab Derxutecan in HER2+ mBC

October 21st 2021

Sara Tolaney, MD, describes trastuzumab deruxtecan and the data that led to its accelerated approval in HER2+ breast cancer.

Historical Perspective of HER2+ Breast Cancer

October 21st 2021

Mark Pegram, MD, provides a historical perspective on recent advancements made in the treatment landscape for patients with HER2-positive breast cancer.

Role of Bronchoscopy in Identifying and Managing ILD

October 15th 2021

Charles A. Powell, MD, MBA, leads a discussion on bronchoscopy’s role in identifying interstitial lung disease.

Optimizing the Management of ILD: Steroids, Therapy Cessation, and Dose Modification

October 15th 2021

A broad review of strategies to manage interstitial lung disease, including steroid use, therapy cessation/rechallenging, and dose reduction.

Managing ILD: Taking Therapeutic Class Into Account

October 8th 2021

Brief considerations for the impact an agent’s therapeutic class can have on how interstitial lung disease should be approached.

Approaching the Management of Interstitial Lung Disease

October 8th 2021

Experts consider the mainstays in ILD management and factors that may dictate one treatment strategy over another.

Dr. Pegram on Unmet Clinical Needs in HER2+ Metastatic Breast Cancer

September 22nd 2021

Mark D. Pegram, MD, discusses unmet clinical needs in HER2-positive metastatic breast cancer.

Dr. Pegram on Considerations for Treatment Selection in HER2+ Breast Cancer

August 4th 2021

Mark D. Pegram, MD, discusses considerations for treatment selection in HER2-positive breast cancer.

Dr. Pegram on the DESTINY-Breast01 Trial With Trastuzumab Deruxtecan in HER2+ Breast Cancer

August 27th 2020

Mark D. Pegram, MD, discusses the results of the phase 2 DESTINY-Breast01 study examining fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.

Dr. Pegram on the Development of Trastuzumab Biosimilars

April 29th 2019

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford's Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women's Cancer Center, discusses the development of trastuzumab biosimilars.

Dr. Pegram on Promising Novel Agents in HER2+ Metastatic Breast Cancer

March 22nd 2019

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses promising novel agents in the treatment of patients with HER2-positive metastatic breast cancer.

Dr. Pegram Discusses Challenges Once Biosimilars Hit US Market

January 19th 2019

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses challenges biosimilars will face once they hit the United States market.

Dr. Pegram on the Manufacturing Process of Biosimilars

December 6th 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the manufacturing process of biosimilars.

Dr. Pegram on Projections of Cost Reductions With Biosimilars

December 4th 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses projections of cost reductions with biosimilars.

Dr. Pegram on Future Impact of Biosimilars in Oncology

November 13th 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the future impact of biosimilars in oncology.

Dr. Pegram Discusses the Use of Neratinib in HER2+ Breast Cancer

May 23rd 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the use of neratinib (Nerlynx) in the treatment of patients with HER2-positive breast cancer.

Dr. Pegram Discusses Adjuvant Pertuzumab in HER2+ Breast Cancer

May 11th 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the use of adjuvant pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

Dr. Pegram on Developing Agents for Patients With HER2+ Breast Cancer and Brain Metastases

April 2nd 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses developing agents for patients with HER2-positive breast cancer who have brain metastases.

NEXT PAGE
PREVIOUS PAGE